IntraOp Medical Introduces Optimal Boost^TM Treatment Method with Mobetron: New European Study Proves Effectiveness of Approach

Sunnyvale, California; October 4, 2007 — IntraOp Medical Corporation (OTCBB: IOPM), a provider of innovative technology solutions for the treatment and eradication of cancer, today announced the introduction of the Optimal Boost approach to breast cancer treatment administered by its flagship product, Mobetron. The Optimal Boost approach was used in a recent study of 378 patients in Europe and proved to significantly reduce breast cancer recurrence rates.

Mobetron is a fully-portable, self-shielding electron-beam linear accelerator that delivers radiation therapy in the operating room at the time of cancer surgery. Mobetron administers intraoperative electron-beam radiation therapy (IOERT) directly to the tumor bed once a cancerous growth has been excised during surgery. The Optimal Boost method, or as it is commonly referred to in breast cancer treatment, the Bio-Boost method, consists of applying a high dosage of radiation to the tumor bed at the time of lumpectomy followed by traditional post-operative radiation therapy.

Because it does not have to pass through healthy skin, organs and tissue, IOERT can be delivered at higher and better cancer-killing doses. Guided by the radiation oncologist's clear view of the site as well as intraoperative ultrasound, IOERT also allows the electron beam to be more accurately targeted. In addition, IOERT eliminates the traditional delay of external radiation therapy, which must be scheduled only after the surgery patient has healed. This can give cancer cells a chance to reconstitute and spread.

In current European studies, the Optimal Boost approach has shown to achieve results that are significantly favorable over traditional treatment methods. At the Breast Center Salzburg in University Hospital Salzburg, Austria, in a nonrandomized study of ipsilateral (same) breast tumor recurrence (IBTR) rates in patients with invasive breast cancer, who had been treated with breast conserving surgery, 378 cases were examined. The first group (188 patients) received only traditional postoperative radiotherapy to the entire breast and the second group (190) patients received intraoperative radiation therapy (an Optimal Boost) in addition to post-operative radiation therapy. The patients were comparable with regard to age, menopausal status, tumor size, histological type, grading and axillary lymph node status.

For the first group, there were 12 cases (6.4%) of ipsilateral breast tumor recurrences and none (0%) in the second group after 51 months. In the first group, there were 24 cases (12.8%) of distant (outside of the breast) recurrences and only 8 instances (4.2%) in the second group. The five-year disease free survival rates were 90.9% for the first group and 95.8% for the second group.

The Optimal Boost approach received further validation in a study that was presented at the San Francisco Breast Conference earlier this year. Dr. Michael Kopp, radiation oncologist at the University of Salzburg, presented the results of pooled analysis from six European cancer centers of 1104 patients that had received an Optimal Boost treatment for their breast cancer. Even though more than 60% of the patients had one or more adverse factors (young age, positive nodes, larger tumor or high histological grade of tumor), there were only five in breast recurrences after a median follow-up period of more than 50 months.

These results show promise for increasing survival as well, since numerous studies show that treatment techniques that increase local control for breast cancer patients at five years will also have a positive impact on patient survival.

"The Optimal Boost methodology reduced overall recurrences of breast cancer substantially," said John Powers, CEO, IntraOp. "These findings are proof-positive that all candidates for breast-conserving therapy should be treated with Mobetron and the Optimal Boost approach."

Powers continued, "Breast cancer patients need to be well educated about their treatment options. The doctor, surgeon, hospital and course of treatment they choose can irrevocably impact the probability of recurrence and survival. Often the course of treatment is dictated by the equipment available at a facility and not by the needs of the patient. Patients must actively seek out the best cancer-treatment facilities, in particular, ones that are equipped with Mobetron or similar IOERT devices."

IntraOp's Mobetron is available in leading institutions in the United States including University of California San Francisco, University of North Carolina, University Hospital Cleveland, Mayo Clinic Phoenix, Ohio State University, Clarion Methodist Hospital Indianapolis, St. Vincent's Hospital in Indianapolis, University of Louisville and next month, St. Joseph's Hospital in Orange, CA.

About Intraop

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intraoperative radiation therapy safely and effectively - for all cancer patients. The company's flagship product, Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use Mobetron as a vital part of their comprehensive cancer program.

Forward-looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.